EP0872552A1
(de)
*
|
1997-04-15 |
1998-10-21 |
Leadd B.V. |
Genabgabe-Vehikel die das Apoptosis VP2 induzierendes Protein und/oder Apoptin exprimiert
|
NL9101680A
(nl)
|
1991-10-04 |
1993-05-03 |
Tno |
Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
|
FR2705686B1
(fr)
*
|
1993-05-28 |
1995-08-18 |
Transgene Sa |
Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
|
US6080569A
(en)
*
|
1993-06-24 |
2000-06-27 |
Merck & Co., Inc. |
Adenovirus vectors generated from helper viruses and helper-dependent vectors
|
ATE272113T1
(de)
*
|
1994-02-16 |
2004-08-15 |
Crucell Holland Bv |
Melanoma-assoziierte antigene, epitope davon und impstoffe gegen melanoma
|
US7252989B1
(en)
*
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
ATE246252T1
(de)
|
1994-08-16 |
2003-08-15 |
Crucell Holland Bv |
Von adenovirus abgeleitete rekombinante vektoren, für gentherapie
|
US5998205A
(en)
*
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
US6281010B1
(en)
*
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
US6265212B1
(en)
*
|
1995-06-15 |
2001-07-24 |
Introgene B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
ATE278794T1
(de)
|
1995-06-15 |
2004-10-15 |
Crucell Holland Bv |
Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
|
US20020068049A1
(en)
*
|
1998-09-10 |
2002-06-06 |
Henderson Daniel R. |
Tissue specific adenoviral vectors
|
CA2224907A1
(en)
|
1995-07-25 |
1997-02-13 |
Introgene B.V. |
Methods and means for targeted gene delivery
|
DK0870044T3
(da)
*
|
1995-12-01 |
2004-08-02 |
Crucell Holland Bv |
Reguleret proteinekspression i stabilt transfekterede pattedyrsceller
|
US20040156861A1
(en)
*
|
1996-07-11 |
2004-08-12 |
Figdor Carl Gustav |
Melanoma associated peptide analogues and vaccines against melanoma
|
WO1998021350A1
(en)
*
|
1996-11-13 |
1998-05-22 |
Board Of Regents, The University Of Texas System |
Diminishing viral gene expression by promoter replacement
|
DE69727492T2
(de)
|
1996-12-05 |
2004-12-16 |
Crucell Holland B.V. |
Genetische modifikation der hämatopoietischen repopulation von stammzellen in primaten
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
JP2000509614A
(ja)
|
1997-03-04 |
2000-08-02 |
バクスター インターナショナル インコーポレイテッド |
アデノウイルスe1−相補性細胞系
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
FR2774699B1
(fr)
*
|
1997-11-17 |
2003-10-03 |
Rhone Poulenc Rorer Sa |
Methode de reduction des evenements de recombinaison homologue
|
WO1999027123A2
(en)
*
|
1997-11-26 |
1999-06-03 |
Board Of Regents, The University Of Texas System |
Modified sv40 viral vectors
|
CA2316414A1
(en)
*
|
1997-12-23 |
1999-07-01 |
Introgene B.V. |
Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
|
ATE344322T1
(de)
|
1998-02-13 |
2006-11-15 |
Koester Hubert |
Verwendung von ribozymen zur bestimmung der funktion von genen
|
US5981225A
(en)
*
|
1998-04-16 |
1999-11-09 |
Baylor College Of Medicine |
Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
|
US6670188B1
(en)
|
1998-04-24 |
2003-12-30 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
EP0959136A1
(de)
|
1998-05-20 |
1999-11-24 |
Introgene B.V. |
Bei einem transporter von kationischen Aminosaüren zielgerichtete Darreichung
|
US6413776B1
(en)
|
1998-06-12 |
2002-07-02 |
Galapagos Geonomics N.V. |
High throughput screening of gene function using adenoviral libraries for functional genomics applications
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
US6900049B2
(en)
*
|
1998-09-10 |
2005-05-31 |
Cell Genesys, Inc. |
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
|
CA2348838A1
(en)
*
|
1998-10-27 |
2000-05-04 |
Crucell Holland B.V. |
Improved aav vector production
|
IT1302403B1
(it)
*
|
1998-11-06 |
2000-09-05 |
Angeletti P Ist Richerche Bio |
Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso.
|
US6929946B1
(en)
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
IL133032A
(en)
*
|
1998-11-20 |
2007-06-03 |
Introgene Bv |
Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
|
EP1016726A1
(de)
*
|
1998-12-30 |
2000-07-05 |
Introgene B.V. |
Gentherapie zur Förderung der Angiogenesis
|
ATE403006T1
(de)
*
|
1999-03-04 |
2008-08-15 |
Crucell Holland Bv |
Verwendung eines adenovirusvektors zur transduktion von synovialen zellen
|
US6869936B1
(en)
|
1999-03-04 |
2005-03-22 |
Crucell Holland B.V. |
Means and methods for fibroblast-like or macrophage-like cell transduction
|
WO2003048348A2
(en)
|
2001-12-07 |
2003-06-12 |
Crucell Holland B.V. |
Production of viruses, viral isolates and vaccines
|
US20050170463A1
(en)
*
|
1999-04-15 |
2005-08-04 |
Abraham Bout |
Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
|
US6855544B1
(en)
|
1999-04-15 |
2005-02-15 |
Crucell Holland B.V. |
Recombinant protein production in a human cell
|
EP2163640B1
(de)
*
|
1999-04-15 |
2011-12-07 |
Crucell Holland B.V. |
Herstellung von rekombinanten Proteinen in einer menschlichen Zelle mit mindestens einem E1 adenovirus Protein
|
US8236561B2
(en)
|
1999-04-15 |
2012-08-07 |
Crucell Holland B.V. |
Efficient production of IgA in recombinant mammalian cells
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
US20060099685A1
(en)
*
|
1999-04-15 |
2006-05-11 |
Yallop Christopher A |
Recombinant expression of factor VIII in human cells
|
US20050164386A1
(en)
*
|
1999-04-15 |
2005-07-28 |
Uytdehaag Alphonsus G. |
Overexpression of enzymes involved in post-translational protein modifications in human cells
|
US7604960B2
(en)
|
1999-04-15 |
2009-10-20 |
Crucell Holland B.V. |
Transient protein expression methods
|
WO2001007571A1
(en)
*
|
1999-04-23 |
2001-02-01 |
Introgene B.V. |
Means and methods for nucleic acid transfer
|
ATE364707T1
(de)
|
1999-05-17 |
2007-07-15 |
Crucell Holland Bv |
Rekombinanter humaner adenovirus-serotyp 35
|
US6492169B1
(en)
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
WO2001002607A1
(en)
*
|
1999-07-06 |
2001-01-11 |
Merck & Co., Inc. |
Adenovirus carrying gag gene hiv vaccine
|
EP1067190A1
(de)
*
|
1999-07-09 |
2001-01-10 |
Introgene B.V. |
Gentherapie zur Erhöhung und/oder Induktion der Angiogenese
|
WO2001020014A1
(en)
*
|
1999-09-10 |
2001-03-22 |
Crucell Holland B.V. |
Modified adenoviral vectors for use in gene therapy
|
EP1083229A1
(de)
*
|
1999-09-10 |
2001-03-14 |
Introgene B.V. |
Veränderte adenovirale Vektoren für die Gentherapie
|
EP1083228A1
(de)
*
|
1999-09-10 |
2001-03-14 |
Introgene B.V. |
Veränderte adenovirale Vektoren für die Gentherapie
|
US6365394B1
(en)
|
1999-09-29 |
2002-04-02 |
The Trustees Of The University Of Pennsylvania |
Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
|
US7115391B1
(en)
|
1999-10-01 |
2006-10-03 |
Genovo, Inc. |
Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
|
DE19955558C2
(de)
*
|
1999-11-18 |
2003-03-20 |
Stefan Kochanek |
Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
|
US6558948B1
(en)
|
1999-11-23 |
2003-05-06 |
Stefan Kochanek |
Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
|
US7521220B2
(en)
*
|
1999-11-26 |
2009-04-21 |
Crucell Holland B.V. |
Production of vaccines
|
US7192759B1
(en)
|
1999-11-26 |
2007-03-20 |
Crucell Holland B.V. |
Production of vaccines
|
US7527961B2
(en)
*
|
1999-11-26 |
2009-05-05 |
Crucell Holland B.V. |
Production of vaccines
|
WO2001044280A2
(en)
*
|
1999-12-14 |
2001-06-21 |
Genovo, Inc. |
Methods and compositions for the manufacture of replication incompetent adenovirus
|
WO2001049325A2
(en)
*
|
2000-01-07 |
2001-07-12 |
Stichting Klinische Farmacologie Groningen |
Gene therapy to promote angiogenesis and/or the treatment of heart failure
|
US7132277B1
(en)
|
2000-01-31 |
2006-11-07 |
Merck & Co., Inc. |
Helper dependent vector system for gene therapy
|
CA2404085A1
(en)
*
|
2000-03-24 |
2001-10-04 |
Cell Genesys, Inc. |
Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising uroplakin-specific transcriptional regulatory sequences, and methods of use thereof
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
EP1157999A1
(de)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
|
KR20010064682A
(ko)
*
|
2000-07-01 |
2001-07-11 |
김재호 |
E1b가 감쇠된 아데노바이러스를 이용한 cd/5-fc및 hsv-1 tk/gcv의 이중 자멸 유전자 시스템
|
US20020164333A1
(en)
*
|
2000-07-10 |
2002-11-07 |
The Scripps Research Institute |
Bifunctional molecules and vectors complexed therewith for targeted gene delivery
|
US7223406B2
(en)
|
2000-07-21 |
2007-05-29 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
WO2002007757A2
(en)
*
|
2000-07-21 |
2002-01-31 |
Lue Tom F |
Prevention and treatment of sexual arousal disorders
|
US20080194022A1
(en)
*
|
2000-08-03 |
2008-08-14 |
Clarke Michael F |
Isolation and use of solid tumor stem cells
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
US6984522B2
(en)
*
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US20040101957A1
(en)
*
|
2001-09-14 |
2004-05-27 |
Emini Emilio A. |
Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
|
US6733993B2
(en)
|
2000-09-15 |
2004-05-11 |
Merck & Co., Inc. |
Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
|
CA2421864A1
(en)
*
|
2000-09-20 |
2002-03-28 |
Crucell Holland B.V. |
Transduction of dendritic cells using adenoviral vectors
|
US7235233B2
(en)
|
2000-09-26 |
2007-06-26 |
Crucell Holland B.V. |
Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
|
US6573092B1
(en)
|
2000-10-10 |
2003-06-03 |
Genvec, Inc. |
Method of preparing a eukaryotic viral vector
|
IL152423A0
(en)
*
|
2001-02-23 |
2003-05-29 |
Novartis Ag |
Novel vector constructs
|
ES2328796T3
(es)
|
2001-03-14 |
2009-11-18 |
Myriad Genetics, Inc. |
Interaccion tsg101-gag y uso de la misma.
|
EP1256803A1
(de)
|
2001-05-07 |
2002-11-13 |
Crucell Holland B.V. |
Verfahren zur Identifizierung von antiviralen Verbindungen
|
US6682929B2
(en)
|
2001-07-23 |
2004-01-27 |
Genvec, Inc. |
Adenovector complementing cells
|
US7229774B2
(en)
|
2001-08-02 |
2007-06-12 |
Regents Of The University Of Michigan |
Expression profile of prostate cancer
|
US20030119771A1
(en)
*
|
2001-08-22 |
2003-06-26 |
Rompaey Luc Van |
Modulators of bone homeostasis identified in a high-throughput screen
|
ATE467680T1
(de)
*
|
2001-10-11 |
2010-05-15 |
Merck Sharp & Dohme |
Hepatitis-c-virus-impfstoff
|
CN1880457B
(zh)
|
2001-10-11 |
2010-05-26 |
麦克公司 |
Ad6重组核酸
|
ATE542904T1
(de)
|
2001-10-29 |
2012-02-15 |
Crucell Holland Bv |
Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
|
EP1456238B1
(de)
*
|
2001-12-17 |
2008-05-28 |
Crucell Holland B.V. |
Herstellung von f(ab')2 fragmenten in saügetierzelle
|
EP1466016A2
(de)
|
2002-01-09 |
2004-10-13 |
Riken Institute Of Physical And Chemical Research |
Krebsprofile
|
EP1516055A4
(de)
*
|
2002-01-24 |
2007-08-08 |
Scripps Research Inst |
Faserschaftmodifikationen für effizientes zielen
|
WO2003070891A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Merck & Co., Inc. |
Method of determining adenovirus particle concentration
|
US7238785B2
(en)
|
2002-03-01 |
2007-07-03 |
Immunomedics, Inc. |
RS7 antibodies
|
US7344873B2
(en)
*
|
2002-03-29 |
2008-03-18 |
Merck & Co., Inc. |
Methods of adenovirus production
|
WO2003087348A1
(en)
*
|
2002-04-08 |
2003-10-23 |
The Johns Hopkins University |
Packaging cell line for diphtheria toxin expressing non-replicating adenovirus
|
DK1497440T3
(da)
*
|
2002-04-25 |
2008-12-01 |
Crucell Holland Bv |
Stabile adenovirale vektorer og fremgangsmåder til propagering deraf
|
PT1497438E
(pt)
*
|
2002-04-25 |
2010-02-04 |
Crucell Holland Bv |
Meios e métodos para a produção de vectores de adenovírus
|
US20030219696A1
(en)
*
|
2002-05-23 |
2003-11-27 |
Moreland Gerald W. |
Method and apparatus for preventing backflow in dental saliva evacuators
|
MXPA04012656A
(es)
|
2002-06-14 |
2005-08-15 |
Immunomedics Inc |
Anticuerpo hpam4 monoclonal humanizado.
|
US7507568B2
(en)
*
|
2002-09-25 |
2009-03-24 |
The Proctor & Gamble Company |
Three dimensional coordinates of HPTPbeta
|
US7226755B1
(en)
*
|
2002-09-25 |
2007-06-05 |
The Procter & Gamble Company |
HPTPbeta as a target in treatment of angiogenesis mediated disorders
|
US20080153083A1
(en)
*
|
2003-10-23 |
2008-06-26 |
Crucell Holland B.V. |
Settings for recombinant adenoviral-based vaccines
|
AU2003288273A1
(en)
*
|
2002-10-23 |
2004-05-13 |
Crucell Holland B.V. |
New settings for recombinant adenoviral-based vaccines
|
US20050221493A1
(en)
*
|
2002-12-04 |
2005-10-06 |
Crucell Holland B.V. |
Recombinant virus production for the manufacturing of vaccines
|
NZ539813A
(en)
|
2002-12-17 |
2008-04-30 |
Crucell Holland Bv |
A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
|
DE60312039T2
(de)
*
|
2002-12-20 |
2007-11-08 |
Chromagenics B.V. |
Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
|
ATE457716T1
(de)
|
2002-12-30 |
2010-03-15 |
Angiotech Int Ag |
Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
|
US20040166091A1
(en)
*
|
2003-02-24 |
2004-08-26 |
Genvec, Inc. |
Materials and methods for treating disorders of the ear
|
WO2004092396A2
(en)
*
|
2003-04-15 |
2004-10-28 |
Novartis Ag |
Flap endonuclease 1 (fen1) regulatory sequences and uses thereof
|
US20070275915A1
(en)
*
|
2003-04-15 |
2007-11-29 |
Cell Genesys, Inc. |
Tmprss2 Regulatory Sequences and Uses Thereof
|
KR101183770B1
(ko)
|
2003-05-09 |
2012-09-17 |
크루셀 홀란드 비.브이. |
E1-불멸화된 세포의 배양물 및 이로부터 생성 수율을 증가시키기 위한 동일물의 배양 방법
|
DE602004027483D1
(de)
*
|
2003-05-23 |
2010-07-15 |
Crucell Holland Bv |
Herstellung von rekombinanten igm in den per.c6 zellen
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
WO2005017149A1
(en)
*
|
2003-06-03 |
2005-02-24 |
Cell Genesys, Inc. |
Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
|
JP2007516693A
(ja)
*
|
2003-06-09 |
2007-06-28 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン |
癌の治療および診断のための組成物および方法
|
US7261882B2
(en)
|
2003-06-23 |
2007-08-28 |
Reagents Of The University Of Colorado |
Methods for treating neuropathic pain by administering IL-10 polypeptides
|
US7026164B2
(en)
|
2003-07-03 |
2006-04-11 |
Cell Genesys, Inc. |
Adenovirus packaging cell lines
|
US20050186178A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Ennist David L. |
Oncolytic adenoviral vectors encoding GM-CSF
|
WO2005033320A1
(en)
*
|
2003-10-02 |
2005-04-14 |
Crucell Holland B.V. |
Packaging cells for recombinant adenovirus
|
US7482156B2
(en)
*
|
2003-10-15 |
2009-01-27 |
Cell Genesys, Inc. |
Hepatocellular carcinoma specific promoter and uses thereof
|
EP1528101A1
(de)
|
2003-11-03 |
2005-05-04 |
ProBioGen AG |
Immortalisierte Vogel-Zelllinien für die Produktion von Viren
|
EP1687032B1
(de)
|
2003-11-14 |
2010-02-24 |
Genvec, Inc. |
Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
|
CA3028774A1
(en)
|
2004-01-23 |
2005-08-04 |
Msd Italia S.R.L. |
Chimpanzee adenovirus vaccine carriers
|
WO2005074633A2
(en)
*
|
2004-02-03 |
2005-08-18 |
The Regents Of The University Of Michigan |
Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
|
DE602005015332D1
(de)
*
|
2004-02-23 |
2009-08-20 |
Crucell Holland Bv |
Verfahren zur Reinigung von Viren
|
US7473418B2
(en)
*
|
2004-03-25 |
2009-01-06 |
Cell Genesys, Inc. |
Pan cancer oncolytic vectors and methods of use thereof
|
AU2005243730B2
(en)
|
2004-04-12 |
2010-05-27 |
Genvec, Inc. |
Method of using adenoviral vectors to induce an immune response
|
WO2005115477A2
(en)
|
2004-04-13 |
2005-12-08 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
EP1773303A2
(de)
*
|
2004-05-25 |
2007-04-18 |
Chimeracore, Inc. |
Selbstmontierendes nanopartikel-wirkstofffreisetzungssystem
|
US7858323B2
(en)
|
2004-06-09 |
2010-12-28 |
The Regents Of The University Of Michigan |
Phage microarray profiling of the humoral response to disease
|
US20060062764A1
(en)
*
|
2004-08-25 |
2006-03-23 |
Seshidar-Reddy Police |
Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
|
CA2589602A1
(en)
*
|
2004-09-01 |
2006-04-13 |
Genvec, Inc. |
Adenoviral vectors able to transduce apcs, potential use in immune response generation
|
EP1804835B9
(de)
|
2004-09-13 |
2012-05-02 |
Genzyme Corporation |
Multimere konstrukte
|
PT1807009E
(pt)
|
2004-10-05 |
2015-02-25 |
Univ California |
Cânula escalonada
|
WO2006042017A2
(en)
|
2004-10-06 |
2006-04-20 |
University Of Rochester |
Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
|
AU2005302408B2
(en)
|
2004-10-28 |
2012-08-09 |
The Government of the United States of America as represented by the Department of Veterans Affairs |
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
|
US8039230B2
(en)
*
|
2004-11-08 |
2011-10-18 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
US20060195935A1
(en)
*
|
2004-11-08 |
2006-08-31 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
CN101090968B
(zh)
*
|
2004-11-08 |
2011-10-26 |
科罗迈吉尼科斯公司 |
高水平表达蛋白质的宿主细胞的选择
|
JP5291341B2
(ja)
|
2004-11-08 |
2013-09-18 |
クロマジェニックス ベー ヴェー |
タンパク質を高レベルで発現する宿主細胞の選定
|
US8999667B2
(en)
*
|
2004-11-08 |
2015-04-07 |
Chromagenics B.V. |
Selection of host cells expressing protein at high levels
|
CN101208425B
(zh)
*
|
2004-12-13 |
2011-01-26 |
坎吉有限公司 |
产生复制缺陷型腺病毒的细胞系
|
AU2006206376B2
(en)
|
2005-01-20 |
2012-03-08 |
University Of Rochester |
Thioredoxin interacting protein (TXNIP) as regulator of vascular function
|
WO2006086284A2
(en)
*
|
2005-02-11 |
2006-08-17 |
Merck & Co., Inc. |
Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
|
WO2006108707A1
(en)
*
|
2005-04-11 |
2006-10-19 |
Crucell Holland B.V. |
Virus purification using ultrafiltration
|
US20060234347A1
(en)
*
|
2005-04-13 |
2006-10-19 |
Harding Thomas C |
Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
|
EP2816118B1
(de)
|
2005-05-31 |
2018-10-17 |
The Regents of the University of Colorado, a body corporate |
Verfahren zur Bereitstellung von Genen
|
US20070099209A1
(en)
*
|
2005-06-13 |
2007-05-03 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
EP1907858A4
(de)
*
|
2005-06-13 |
2009-04-08 |
Univ Michigan |
Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
|
ES2948791T3
(es)
*
|
2005-06-17 |
2023-09-19 |
Msd Italia Srl |
Vacuna de ácido nucleico contra el virus de la hepatitis C
|
CN101228267B
(zh)
*
|
2005-07-22 |
2013-01-23 |
克鲁塞尔荷兰公司 |
生产冠状病毒的细胞系
|
US8450055B2
(en)
*
|
2005-08-31 |
2013-05-28 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
US9651543B2
(en)
|
2005-08-31 |
2017-05-16 |
The United States Of America As Represented By The Secretary Of The Navy |
Malaria antigen screening method
|
US8765146B2
(en)
|
2005-08-31 |
2014-07-01 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
AU2006291054B2
(en)
|
2005-09-12 |
2011-10-13 |
The Brigham And Women's Hospital, Inc. |
Recurrent gene fusions in prostate cancer
|
US8652467B2
(en)
*
|
2005-10-14 |
2014-02-18 |
The Regents Of The University Of Michigan |
Dek protein compositions and methods of using the same
|
US7794951B2
(en)
*
|
2005-10-18 |
2010-09-14 |
University Of Massachusetts Medical School |
SREBP2gc transcription factors and uses thereof
|
WO2007053648A2
(en)
*
|
2005-10-31 |
2007-05-10 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
AU2006308870B2
(en)
|
2005-10-31 |
2012-08-16 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
BRPI0618441B8
(pt)
|
2005-11-10 |
2021-07-27 |
Genvec Inc |
vetor adenoviral
|
CA2633087C
(en)
*
|
2005-12-12 |
2014-12-02 |
Canji, Inc. |
Adenoviral expression vectors
|
AR059089A1
(es)
|
2006-01-20 |
2008-03-12 |
Genzyme Corp |
Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
|
BRPI0707900A2
(pt)
|
2006-02-09 |
2011-05-10 |
Genzyme Corp |
distribuiÇço intraventricular lenta
|
WO2008121102A2
(en)
*
|
2006-02-21 |
2008-10-09 |
The Regents Of The University Of Michigan |
Hedgehog signaling pathway antagonist cancer treatment
|
EP1996705B1
(de)
*
|
2006-03-20 |
2011-08-31 |
ChromaGenics B.V. |
Die expression verstärkende dna-fragmente, deren verwendung und verfahren zum finden dieser
|
DE602007005366D1
(de)
*
|
2006-04-07 |
2010-04-29 |
Chimeros Inc |
Zusammensetzungen und verfahren zur behandlung von b-zellen-malignomen
|
SMP200800060B
(it)
*
|
2006-04-07 |
2009-07-14 |
Procter & Gamble |
Anticorpi che legano la proteina umana tirosina fosfatasi beta (hptbeta) e loro usi
|
US20100159450A1
(en)
|
2006-06-23 |
2010-06-24 |
Susanne Wagner |
Dpyd gene variants and use thereof
|
JP2009541333A
(ja)
*
|
2006-06-23 |
2009-11-26 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
修飾リボヌクレアーゼ
|
US7795444B2
(en)
*
|
2006-06-27 |
2010-09-14 |
Warner Chilcott Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US7589212B2
(en)
|
2006-06-27 |
2009-09-15 |
Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US8846685B2
(en)
|
2006-06-27 |
2014-09-30 |
Aerpio Therapeutics Inc. |
Human protein tyrosine phosphatase inhibitors and methods of use
|
US7622593B2
(en)
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
HUE034299T2
(en)
|
2006-07-14 |
2018-02-28 |
Patheon Holdings I B V |
An improved method for cell culture
|
EP2049151A4
(de)
|
2006-07-17 |
2010-03-24 |
Quintessence Biosciences Inc |
Verfahren und zusammensetzungen zur behandlung von krebs
|
US20080261216A1
(en)
*
|
2006-09-08 |
2008-10-23 |
The Regents Of The University Of Michigan |
HERV Group II Viruses In Lymphoma And Cancer
|
CA2675022A1
(en)
*
|
2007-01-09 |
2008-07-17 |
Genvec, Inc. |
Adenoviral vector-based malaria vaccines
|
US11371194B2
(en)
*
|
2007-01-19 |
2022-06-28 |
Brock Usa, Llc |
Base for turf system
|
EP2106439B1
(de)
|
2007-01-24 |
2014-11-12 |
The Regents of the University of Michigan |
Zusammensetzungen und verfahren zur behandlung und diagnostizierung von pankreaskrebs
|
WO2008112540A2
(en)
*
|
2007-03-09 |
2008-09-18 |
Vectorlogics, Inc. |
Cells for adenovirus vector and protein production
|
WO2008124165A2
(en)
*
|
2007-04-09 |
2008-10-16 |
Chimeros, Inc. |
Self-assembling nanoparticle drug delivery system
|
US20090324596A1
(en)
*
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
CA2692441C
(en)
|
2007-07-06 |
2020-01-21 |
The Regents Of The University Of Michigan |
Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer
|
WO2009026152A1
(en)
|
2007-08-16 |
2009-02-26 |
The Regents Of The University Of Michigan |
Metabolomic profiling of prostate cancer
|
DE102007041655A1
(de)
|
2007-09-03 |
2009-03-05 |
Medicyte Gmbh |
Vermehrung von primären Zellen und deren Verwendung
|
JP2010540681A
(ja)
*
|
2007-10-08 |
2010-12-24 |
クインテッセンス バイオサイエンシズ,インコーポレーテッド |
リボヌクレアーゼに基づく治療のための組成物及び方法
|
TWI488640B
(zh)
|
2008-04-16 |
2015-06-21 |
Ferring Int Ct Sa |
藥學製劑
|
US8518884B2
(en)
|
2008-04-25 |
2013-08-27 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
|
US8193151B2
(en)
*
|
2008-04-25 |
2012-06-05 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias
|
CA2728477C
(en)
*
|
2008-07-15 |
2017-02-28 |
Crucell Holland B.V. |
Scalable process for culturing per.c6 cells and producing products therefrom
|
EP2342321B1
(de)
|
2008-09-17 |
2018-04-11 |
Isogenis, Inc. |
Konstruktion von genzuführungsvektoren auf basis eines vollständig deletierten adenovirus und verwendungen davon
|
NZ592338A
(en)
|
2008-09-26 |
2012-11-30 |
Oncomed Pharm Inc |
Frizzled-binding agents and uses thereof
|
JP2012504423A
(ja)
|
2008-10-01 |
2012-02-23 |
クインテッセンス バイオサイエンシズ,インコーポレーテッド |
治療用リボヌクレアーゼ
|
US20110184154A1
(en)
*
|
2008-10-17 |
2011-07-28 |
Percivia Llc |
Cell broth clarification and host cell protein removal
|
WO2010060719A1
(en)
*
|
2008-11-03 |
2010-06-03 |
Crucell Holland B.V. |
Method for the production of adenoviral vectors
|
CN102639709A
(zh)
|
2009-01-09 |
2012-08-15 |
密歇根大学董事会 |
癌症中的复现性基因融合体
|
US9096555B2
(en)
|
2009-01-12 |
2015-08-04 |
Aerpio Therapeutics, Inc. |
Methods for treating vascular leak syndrome
|
EP2382474B1
(de)
|
2009-01-20 |
2015-03-04 |
Transgene SA |
Lösliches icam-1 als biomarker zur vorhersage einer therapeutischen antwort
|
WO2010107991A2
(en)
|
2009-03-18 |
2010-09-23 |
Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
|
KR20110138354A
(ko)
|
2009-03-24 |
2011-12-27 |
트랜스진 에스.에이. |
환자를 모니터링하기 위한 바이오마커
|
WO2010120874A2
(en)
|
2009-04-14 |
2010-10-21 |
Chimeros, Inc. |
Chimeric therapeutics, compositions, and methods for using same
|
US20120058493A1
(en)
|
2009-04-17 |
2012-03-08 |
Bruce Acres |
Biomarker for monitoring patients
|
EA025021B1
(ru)
|
2009-04-23 |
2016-11-30 |
Круселл Холланд Б.В. |
РЕКОМБИНАНТНЫЙ α1-АНТИТРИПСИН ЧЕЛОВЕКА
|
CA2765099A1
(en)
|
2009-06-10 |
2010-12-16 |
New York University |
Phosphorylated tau peptide for use in the treatment of tauopathy
|
US8883832B2
(en)
|
2009-07-06 |
2014-11-11 |
Aerpio Therapeutics Inc. |
Compounds, compositions, and methods for preventing metastasis of cancer cells
|
CN105412094A
(zh)
|
2009-07-06 |
2016-03-23 |
爱尔皮奥治疗有限公司 |
用于防止癌细胞转移的化合物、组合物和方法
|
WO2011003615A2
(en)
|
2009-07-08 |
2011-01-13 |
Glycotope Gmbh |
Perfusion bioreactor
|
CN102483405B
(zh)
|
2009-07-10 |
2015-12-02 |
特朗斯吉有限公司 |
用于选择患者的生物标志物及相关方法
|
EP2454364B1
(de)
*
|
2009-07-16 |
2014-04-23 |
Crucell Holland B.V. |
Herstellung von poliovirus mit hohen titern zur impfstofffherstellung
|
NZ598000A
(en)
|
2009-08-07 |
2013-10-25 |
Transgene Sa |
Composition for treating hbv infection
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
KR101749779B1
(ko)
*
|
2009-10-15 |
2017-06-21 |
크루셀 홀란드 비.브이. |
아데노바이러스 입자의 정제 방법
|
EA028875B1
(ru)
|
2009-10-15 |
2018-01-31 |
Янссен Вэксинс Энд Превеншн Б.В. |
Способ очистки аденовирусных частиц из клеточной суспензии
|
WO2011047316A1
(en)
|
2009-10-16 |
2011-04-21 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Nucleic acid sequences encoding expandable hiv mosaic proteins
|
WO2011057254A2
(en)
|
2009-11-09 |
2011-05-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Simian adenoviral vector-based vaccines
|
WO2011057248A2
(en)
|
2009-11-09 |
2011-05-12 |
Genvec, Inc. |
Simian adenovirus and methods of use
|
DK2521566T3
(en)
|
2010-01-08 |
2014-12-08 |
Profibrix Bv |
Fibrinogen preparations enriched with fibrinogen with an extended alpha chain
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
EA023816B1
(ru)
|
2010-02-15 |
2016-07-29 |
Круселл Холланд Б.В. |
СПОСОБ ПРОДУЦИРОВАНИЯ ВИРУСНЫХ ЧАСТИЦ Ad26
|
EP3450979A3
(de)
|
2010-03-17 |
2019-04-24 |
The Regents of The University of Michigan |
Verwendung von phagenepitopen zur profilierung einer immunreaktion
|
US9682133B2
(en)
|
2010-03-17 |
2017-06-20 |
Cornell University |
Disrupted adenovirus-based vaccine against drugs of abuse
|
US20130195800A1
(en)
|
2010-03-23 |
2013-08-01 |
Intrexon Corporation |
Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
|
NZ602700A
(en)
|
2010-04-01 |
2014-10-31 |
Oncomed Pharm Inc |
Frizzled-binding agents and uses thereof
|
WO2012021730A2
(en)
|
2010-08-11 |
2012-02-16 |
Genvec, Inc. |
Respiratory syncytial virus (rsv) vaccine
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
CA2808556A1
(en)
|
2010-09-20 |
2012-03-29 |
Crucell Holland B.V. |
Therapeutic vaccination against active tuberculosis
|
AU2011310838B2
(en)
|
2010-09-27 |
2015-11-05 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
DE102010041958A1
(de)
|
2010-10-04 |
2012-04-05 |
Medicyte Gmbh |
Geeignete Hepatozyten für in-vitro Genotoxitätstests
|
WO2012083297A2
(en)
|
2010-12-17 |
2012-06-21 |
Genvec, Inc. |
Adenoviral vectors with modified hexon regions
|
EP2654786B1
(de)
|
2010-12-20 |
2019-02-20 |
GenVec, Inc. |
Auf adenovirusvektor basierender impfstoff gegen denguefieber
|
US20130344053A1
(en)
|
2010-12-28 |
2013-12-26 |
University Of Rochester |
Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides
|
US9428565B2
(en)
|
2011-01-31 |
2016-08-30 |
The General Hospital Corporation |
Treatment and bioluminescent visualization using multimodal TRAIL molecules
|
US9402919B2
(en)
|
2011-03-04 |
2016-08-02 |
Intrexon Corporation |
Vectors conditionally expressing protein
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
EP2729173B1
(de)
|
2011-07-06 |
2016-06-15 |
Sykehuset Sorlandet HF |
Auf egfr zielende therapie
|
TWI575070B
(zh)
|
2011-07-12 |
2017-03-21 |
傳斯堅公司 |
Hbv聚合酶突變體
|
LT2753346T
(lt)
|
2011-09-07 |
2020-08-10 |
Mount Sinai School Of Medicine |
Ceramidazė ir ląstelių diferenciacija
|
WO2013036973A2
(en)
|
2011-09-09 |
2013-03-14 |
Biomed Realty, L.P. |
Methods and compositions for controlling assembly of viral proteins
|
TW201321016A
(zh)
|
2011-09-29 |
2013-06-01 |
Transgene Sa |
免疫療法組成物及用於治療c型肝炎病毒感染之療程(二)
|
WO2013045658A1
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
US9580476B2
(en)
|
2011-10-05 |
2017-02-28 |
Genvec, Inc. |
Adenoviral vector-based respiratory syncytial virus (RSV) vaccine
|
CA2850627A1
(en)
|
2011-10-05 |
2013-04-11 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
JP6757119B2
(ja)
|
2011-10-05 |
2020-09-16 |
ジェンヴェック エルエルシー |
アーフェンアデノウイルス(ゴリラ)又はアデノウイルスベクター、及び使用方法
|
US9617560B2
(en)
|
2011-10-05 |
2017-04-11 |
Genvec, Inc. |
Simian (gorilla) adenovirus or adenoviral vectors and methods of use
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
WO2013077645A1
(ko)
*
|
2011-11-24 |
2013-05-30 |
주식회사 바이로메드 |
아데노바이러스 생산 신규 세포주 및 그의 용도
|
WO2013082106A1
(en)
|
2011-12-02 |
2013-06-06 |
The General Hospital Corporation |
Differentiation into brown adipocytes
|
US9175312B2
(en)
|
2011-12-08 |
2015-11-03 |
Virovek Incorporation |
Vectors harboring toxic genes, methods and uses therefor
|
US20150157700A1
(en)
|
2012-02-02 |
2015-06-11 |
GanVec, Inc. |
Adenoviral vector-based malaria vaccine
|
WO2013119880A1
(en)
|
2012-02-07 |
2013-08-15 |
Global Bio Therapeutics Usa, Inc. |
Compartmentalized method of nucleic acid delivery and compositions and uses thereof
|
EA034284B1
(ru)
|
2012-03-12 |
2020-01-24 |
Янссен Вэксинс Энд Превеншн Б.В. |
Частицы рекомбинантного трансгенсодержащего аденовируса с 5'-концевыми нуклеотидами ctatctat
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
US9119813B2
(en)
|
2012-03-22 |
2015-09-01 |
Crucell Holland B.V. |
Vaccine against RSV
|
BR112014023196B1
(pt)
|
2012-03-22 |
2021-09-08 |
Janssen Vaccines & Prevention B.V. |
Vacinas contra o vírus sincicial respiratório (rsv), seu método de produção, e ácido nucleico recombinante isolado
|
EP2855669B1
(de)
|
2012-05-29 |
2018-10-10 |
GenVec, Inc. |
Modifizierte serotyp-28-adenovirusvektoren
|
WO2013180967A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
BR112015000530A2
(pt)
|
2012-07-10 |
2018-08-28 |
Transgene Sa |
vacina de antígeno micobacteriano.
|
BR112015002268A2
(pt)
|
2012-08-03 |
2017-11-07 |
Sanofi Pasteur |
produção de vírus influenza infecciosos
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
WO2014063155A1
(en)
|
2012-10-21 |
2014-04-24 |
University Of Rochester |
Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
|
JP2015536933A
(ja)
|
2012-10-23 |
2015-12-24 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Wnt経路結合剤を用いて神経内分泌腫瘍を処置する方法
|
CA3200425A1
(en)
|
2012-11-16 |
2014-05-22 |
Peter ABBINK |
Recombinant adenoviruses and use thereof
|
AU2013362134B2
(en)
|
2012-12-21 |
2018-07-05 |
Sykehuset Sorlandet Hf |
EGFR targeted therapy of neurological disorders and pain
|
JP2016510411A
(ja)
|
2013-02-04 |
2016-04-07 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Wnt経路インヒビターによる処置の方法およびモニタリング
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
KR101606910B1
(ko)
|
2013-03-29 |
2016-04-04 |
충북보건과학대학교 산학협력단 |
아데노바이러스 벡터 생산용 a549 기반 세포주
|
CA3182572A1
(en)
|
2013-04-17 |
2014-10-23 |
Genzyme Corporation |
Use of an il17 inhibitor for treating and preventing macular degeneration
|
US9822418B2
(en)
|
2013-04-22 |
2017-11-21 |
Icahn School Of Medicine At Mount Sinai |
Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis
|
CN105188745B
(zh)
|
2013-04-25 |
2019-10-18 |
扬森疫苗与预防公司 |
稳定化的可溶性融合前rsv f多肽
|
CA2913155A1
(en)
|
2013-05-21 |
2014-11-27 |
President And Fellows Of Harvard College |
Engineered heme-binding compositions and uses thereof
|
BR112015031509B1
(pt)
|
2013-06-17 |
2023-05-09 |
Janssen Vaccines & Prevention B.V. |
Polipeptídeo de fusão (f) do vírus sincicial respiratório (rsv) pré- fusão recombinante e composição que o compreende
|
ES2525768B1
(es)
*
|
2013-06-24 |
2015-10-07 |
Curaxis, S.L. |
Procedimiento para la producción de proteínas recombinantes glicosiladas.
|
WO2015021443A1
(en)
|
2013-08-08 |
2015-02-12 |
Global Bio Therapeutics Usa, Inc. |
Clamp device for minimally invasive procedures and uses thereof
|
EP3046536B1
(de)
|
2013-09-19 |
2018-11-28 |
Janssen Vaccines & Prevention B.V. |
Verbesserte adenovirusformulierung
|
US10421986B2
(en)
|
2013-09-30 |
2019-09-24 |
Janssen Vaccines & Prevention B.V. |
Method for the clarification of high-density crude cell culture harvest
|
CA2936131A1
(en)
|
2014-01-09 |
2015-07-16 |
Transgene Sa |
Fusion of heterooligomeric mycobacterial antigens
|
WO2015120309A1
(en)
|
2014-02-06 |
2015-08-13 |
Genzyme Corporation |
Compositions and methods for treating and preventing macular degeneration
|
EP2927685A1
(de)
|
2014-04-02 |
2015-10-07 |
Medicyte GmbH |
Geeignete Hepatozyten für In-vitro-Hepatitistests
|
ES2733489T3
(es)
|
2014-07-24 |
2019-11-29 |
Janssen Vaccines & Prevention Bv |
Proceso de purificación de poliovirus a partir de cultivos celulares
|
IL292577A
(en)
|
2014-09-07 |
2022-06-01 |
Selecta Biosciences Inc |
Methods and preparations for attenuating immune responses of gene editing in an antiviral transfer system
|
JP7095990B2
(ja)
|
2014-09-18 |
2022-07-05 |
シーダーズ-サイナイ メディカル センター |
線維症を治療するための組成物及び方法
|
TWI710635B
(zh)
|
2014-10-09 |
2020-11-21 |
美商珍維克公司 |
編碼人類無調同源物-1(hath1)之腺病毒載體
|
MD3215187T2
(ro)
|
2014-11-04 |
2019-02-28 |
Janssen Vaccines & Prevention Bv |
Vaccinuri HPV16 terapeutice
|
CA2976826A1
(en)
|
2015-02-19 |
2016-08-25 |
Ewoud VAN TRICHT |
Method for quantification of virus particles using capillary zone electrophoresis
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
ES2836432T3
(es)
|
2015-03-18 |
2021-06-25 |
Janssen Vaccines & Prevention Bv |
Ensayos para sistemas de expresión recombinante
|
PL3283634T3
(pl)
|
2015-04-14 |
2019-10-31 |
Janssen Vaccines & Prevention Bv |
Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
|
EP3283529B1
(de)
|
2015-04-17 |
2023-06-07 |
The General Hospital Corporation |
Wirkstoffe, systeme und verfahren zur behandlung von krebs
|
EP4194001A1
(de)
|
2015-04-22 |
2023-06-14 |
Cedars-Sinai Medical Center |
Enterisch verabreichte bittere oligopeptide zur behandlung von typ-2-diabetes und fettleibigkeit
|
BR112017028449A2
(pt)
|
2015-07-07 |
2018-09-04 |
Janssen Vaccines & Prevention Bv |
polipeptídeos rsv f pré-fusão solúveis estabilizados
|
JP7189014B2
(ja)
|
2015-07-07 |
2022-12-13 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Rsvに対するワクチン
|
SG10202001501QA
(en)
|
2015-08-20 |
2020-04-29 |
Janssen Vaccines & Prevention Bv |
Therapeutic hpv18 vaccines
|
EA036412B1
(ru)
|
2015-10-06 |
2020-11-09 |
Янссен Вэксинс Энд Превеншн Б.В. |
Способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с пластиком, и применение 2-гидроксипропил--циклодекстрина для защиты аденовируса
|
US20200208173A1
(en)
*
|
2015-10-30 |
2020-07-02 |
Seracare Life Sciences, Inc. |
Adenovirus control virus
|
EP3371211A4
(de)
|
2015-11-04 |
2019-08-21 |
Icahn School of Medicine at Mount Sinai |
Verfahren zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
|
US10377801B2
(en)
|
2015-11-04 |
2019-08-13 |
Northwestern University |
Amelioration of chronic kidney disease
|
KR20220041966A
(ko)
|
2016-04-05 |
2022-04-01 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 용해성 융합-전 rsv f 단백질
|
MY193584A
(en)
|
2016-04-05 |
2022-10-19 |
Janssen Vaccines & Prevention Bv |
Vaccine against rsv
|
US11246868B2
(en)
|
2016-04-26 |
2022-02-15 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
JP7053491B2
(ja)
|
2016-05-02 |
2022-04-12 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
治療用hpvワクチン組み合わせ
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
JP7046835B2
(ja)
|
2016-05-12 |
2022-04-04 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
強力でバランスのとれた双方向性プロモーター
|
MY194419A
(en)
|
2016-05-30 |
2022-11-30 |
Janssen Vaccines & Prevention Bv |
Stabilized pre-fusion rsv f proteins
|
MX2018015540A
(es)
|
2016-06-20 |
2019-04-11 |
Janssen Vaccines & Prevention Bv |
Promotor bidireccional potente y equilibrado.
|
US11091795B2
(en)
|
2016-07-11 |
2021-08-17 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for diagnosing and treating arrhythmias
|
US10744196B2
(en)
|
2016-07-14 |
2020-08-18 |
Janssen Vaccines & Prevention B.V. |
HPV vaccines
|
CA3038968A1
(en)
|
2016-09-30 |
2018-04-05 |
Genvec, Inc. |
Adenovectors for delivery of therapeutic genetic material into t cells
|
WO2018069316A2
(en)
|
2016-10-10 |
2018-04-19 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
AU2018205496A1
(en)
|
2017-01-07 |
2019-07-25 |
Selecta Biosciences, Inc. |
Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
|
WO2018140630A1
(en)
|
2017-01-25 |
2018-08-02 |
Northwestern University |
Autophagy inducers for treatment of cns conditions
|
JP6721797B2
(ja)
|
2017-02-09 |
2020-07-15 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. |
異種遺伝子発現のための強力で短いプロモーター
|
US11781116B2
(en)
|
2017-02-17 |
2023-10-10 |
Lonza Ltd. |
Mammalian cells for producing adeno-associated viruses
|
CN110832072B
(zh)
|
2017-04-21 |
2023-11-07 |
真基因太科公司 |
用于生产非复制型腺病毒的细胞系以及制备所述细胞系的方法
|
CA3061278A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
KR20200053518A
(ko)
|
2017-09-15 |
2020-05-18 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 면역의 안전한 유도를 위한 방법
|
BR112020007157A2
(pt)
|
2017-10-13 |
2020-09-24 |
Selecta Biosciences, Inc. |
métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
|
CN111356466A
(zh)
|
2017-10-31 |
2020-06-30 |
扬森疫苗与预防公司 |
腺病毒及其用途
|
SG11202003399TA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus and uses thereof
|
CN111295449B
(zh)
|
2017-10-31 |
2023-12-05 |
扬森疫苗与预防公司 |
腺病毒载体及其用途
|
CN111372943B
(zh)
|
2017-10-31 |
2023-12-05 |
扬森疫苗与预防公司 |
腺病毒及其用途
|
AU2018372906A1
(en)
|
2017-11-22 |
2020-06-11 |
The Regents Of The University Of Michigan |
Compositions and methods for treating cancer
|
US11773142B2
(en)
|
2017-12-11 |
2023-10-03 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and uses thereof
|
AU2019212180A1
(en)
|
2018-01-23 |
2020-07-16 |
Janssen Vaccines & Prevention B.V. |
Influenza virus vaccines and uses thereof
|
AU2019231652A1
(en)
|
2018-03-06 |
2020-10-01 |
Precigen, Inc. |
Hepatitis B vaccines and uses of the same
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
KR20220005002A
(ko)
|
2019-04-25 |
2022-01-12 |
얀센 백신스 앤드 프리벤션 비.브이. |
재조합 인플루엔자 항원
|
BR112021021566A2
(pt)
|
2019-04-28 |
2022-04-19 |
Selecta Biosciences Inc |
Métodos para tratamento de indivíduos com imunidade preexistente a vetores de transferência viral
|
CN113924113A
(zh)
|
2019-05-15 |
2022-01-11 |
扬森疫苗与预防公司 |
季节性流感疫苗与基于腺病毒的呼吸道合胞病毒疫苗的共同施用
|
AU2020275910A1
(en)
|
2019-05-15 |
2021-11-04 |
Janssen Vaccines & Prevention B.V. |
Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
|
EP3969046A1
(de)
|
2019-05-16 |
2022-03-23 |
Janssen Vaccines & Prevention B.V. |
Verfahren zur induzierung einer sicheren immunantwort gegen das poliovirus
|
CN114206396A
(zh)
|
2019-05-28 |
2022-03-18 |
西莱克塔生物科技公司 |
用于减弱抗病毒转移载体免疫应答的方法和组合物
|
WO2021043869A1
(en)
|
2019-09-05 |
2021-03-11 |
Janssen Vaccines & Prevention B.V. |
Influenza virus vaccines and uses thereof
|
JP2022551107A
(ja)
|
2019-10-03 |
2022-12-07 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルスベクターおよびその使用
|
AU2020385683A1
(en)
|
2019-11-18 |
2022-06-30 |
Janssen Biotech, Inc. |
Vaccines based on mutant CALR and JAK2 and their uses
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
AU2021357520A1
(en)
|
2020-03-05 |
2022-09-29 |
Neotx Therapeutics Ltd. |
Methods and compositions for treating cancer with immune cells
|
JP2023521194A
(ja)
|
2020-04-13 |
2023-05-23 |
ヤンセン バイオテツク,インコーポレーテツド |
Psma及びsteap1ワクチン並びにそれらの使用
|
EP4139355A1
(de)
|
2020-04-21 |
2023-03-01 |
Jjp Biologics Sp. Z O.O. |
Humanisierte anti-human-cd89-antikörper und verwendungen davon
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
WO2022009051A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
A method for determining responsiveness to prostate cancer treatment
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
EP4178605A1
(de)
|
2020-07-13 |
2023-05-17 |
Transgene |
Behandlung von immundepression
|
EP4196137A1
(de)
|
2020-08-11 |
2023-06-21 |
Musculoskeletal Transplant Foundation |
Verfahren zur behandlung von herzerkrankungen mit zusammensetzungen aus plazenta
|
WO2023017494A1
(en)
|
2021-08-13 |
2023-02-16 |
Triovance Holding Llc |
A skin substitute composition and methods of producing and using the same
|
WO2023064367A1
(en)
|
2021-10-12 |
2023-04-20 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
WO2023172624A1
(en)
|
2022-03-09 |
2023-09-14 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
EP4338727A1
(de)
|
2022-09-14 |
2024-03-20 |
Roquette Freres |
Adenovirus-formulierungen
|